Insider Buying: Biosig Technologies (NASDAQ:STEX) Major Shareholder Acquires 1,000,000 Shares of Stock

Biosig Technologies, Inc. (NASDAQ:STEX) major shareholder Frank Giustra purchased 1,000,000 shares of the stock in a transaction dated Friday, January 23rd. The shares were acquired at an average price of $3.00 per share, for a total transaction of $3,000,000.00. Following the acquisition, the insider directly owned 1,178,205 shares of the company’s stock, valued at $3,534,615. This represents a 561.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Biosig Technologies Trading Up 7.4%

Biosig Technologies stock traded up $0.25 during mid-day trading on Tuesday, hitting $3.65. The company’s stock had a trading volume of 3,070,785 shares, compared to its average volume of 1,343,926. Biosig Technologies, Inc. has a 52-week low of $0.40 and a 52-week high of $14.11. The company has a market cap of $542.43 million, a P/E ratio of -2.70 and a beta of 1.48.

Analyst Ratings Changes

Separately, Weiss Ratings started coverage on shares of Biosig Technologies in a research report on Friday. They set a “sell (d-)” rating on the stock. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Biosig Technologies currently has an average rating of “Sell”.

Biosig Technologies News Summary

Here are the key news stories impacting Biosig Technologies this week:

• Positive Sentiment: Significant insider buying by company insiders — Director Morgan Lee Lekstrom increased his holdings with multiple purchases (totaling ~69,500 shares across Jan. 23–27) and CIO Mitchell Young Williams bought 51,511 shares, signaling management confidence at ~ $3.03–$3.30 per share. This buying often supports near-term demand for the stock. Insider Filing
• Neutral Sentiment: Trading activity is elevated vs. the stock’s average volume, which can amplify price moves while these corporate items digest in the market. (Background volume and price context: MarketBeat STEX page.) MarketBeat STEX
• Negative Sentiment: Streamex (ticker STEX) completed its underwritten offering and the underwriters’ over‑allotment was exercised in full, increasing total shares issued and producing roughly $40.25M gross proceeds. The deal materially enlarged the share count, which is dilutive and can weigh on the stock despite the cash infusion. GlobeNewswire: Over-Allotment
• Negative Sentiment: Fresh sell-side/ratings pressure — Weiss Ratings initiated coverage with a “sell (d-)” designation, and the stock’s consensus on MarketBeat remains on the sell side, which could limit upside while investor attention focuses on dilution and fundamentals. MarketBeat: Coverage

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.